Skip to main content
Video

Analyzing the Use of CAR-T Therapy for the Treatment of Multiple Myeloma


December 05, 2020

Deepu Madduri, MD - Assistant Professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel  Deepu Madduri, MD, assistant professor, Hematology and Medical Oncology of the Mount Sinai Hospital, Mount Sinai Beth Israel, discusses the results of the CARTITUDE-1 study, which analyzed ciltacabtagene autoleucel, a CAR-T-cell therapy with 2 B-cell maturation antigen–targeting single-domain antibodies, for the treatment of patients with relapsed/refractory multiple myeloma.

 

Reference:

Madduri D, Berdeja J, Usmani S, et al. CARTITUDE-1: Phase 1b/2 Study of Ciltacabtagene Autoleucel, a B-Cell Maturation Antigen–Directed Chimeric Antigen Receptor T Cell Therapy, in Relapsed/Refractory Multiple Myeloma (Abstract 177). https://ash.confex.com/ash/2020/webprogram/Paper136307.html. December 5, 2020. 

Agree or disagree with an article? Share your professional thoughts on an article you read.

Your Name
1 + 5 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Back to Top